Navigation Links
Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
Date:1/4/2011

ROCHESTER, N.Y., Jan. 4, 2011 /PRNewswire/ -- Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO)

VX15/2503 is a novel humanized antibody that blocks the activity of semaphorin 4D (SEMA4D).  It is the first of two of the Company's therapeutic antibodies expected to begin clinical trials this year. "Advancing VX15 into the clinical stage of development is an exciting achievement for Vaccinex, and a testament to the experience and outstanding capabilities of our research and development teams," said Ray Watkins, Senior Vice President and Chief Operating Officer of the company.

"SEMA4D is an exciting therapeutic target with remarkable biological properties relevant to several disease processes," said Dr. Maurice Zauderer, President and Chief Executive Officer of Vaccinex.  As reflected in its name, semaphorin, the molecule guides the activation and movement of different cell types in different ways.  For example, SEMA4D promotes migration of tumor cells that metastasize to new locations as well as the outgrowth of cells that form new blood vessels required to provide nutrients and energy to tumors.  It is anticipated that, by blocking this signal, the anti-SEMA4D antibody will both inhibit the growth of primary tumors and limit metastases to new sites.  "This is important," Dr. Zauderer said, "because if tumors did not metastasize, then surgeons could cure cancer."  In other tissues and disease processes, for example damage to neurons in demyelinating diseases such as multiple sclerosis (MS)
'/>"/>

SOURCE Vaccinex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
2. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
3. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
4. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
5. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
6. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
7. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
8. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
9. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Research and Markets ( ... "Global Bioinformatics Market Outlook 2019" report to their ... mark of around US$ 3.7 Billion in 2013 with ... around 19% during 2015-2019 The report is ... of global developments and opportunities listed in the section ...
(Date:4/21/2015)... 21, 2015 Research and Markets ... the "Complete 2015-16 Induced Pluripotent Stem Cell ... Stem cell research and experimentation have ... as stem cells have the unique ability to ... nature allows them to differentiate into a wide ...
(Date:4/21/2015)... , April 21, 2015 The ... $313.0 million in 2014 to $605.1 million by 2019, at ... Browse through the TOC of ... analysis of the industry trends and segments, with help ... Early buyers will receive 10% ...
(Date:4/21/2015)... Contract Research Organization XenoTech, LLC , a division of ... ft2 facility. The planned move will double the size ... St. in Lenexa, KS. The new facility, boasting nearly ... remain in the Kansas City metro area, just blocks away ... ago. Remaining in the Kansas City area maintains the ...
Breaking Biology Technology:Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 2Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 3Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3
... 7 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... to present a corporate overview at the,ThinkEquity Partners, G5: ... p.m. Eastern Time (10:30 a.m. Pacific Time) at the ... the live audio broadcast or the subsequent archived,recording, log ...
... and Risk ... Distant Sites, REHOVOT, Israel and NEW YORK, September 7 ... in the field of,microRNA and RNAi, announced today it will ... significant potential of microRNA,profiles to develop a diagnostic test for ...
... 5:30-7:30 p.m. (ET), SAN DIEGO, Sept. 7 ... developing products for,minimally disruptive surgical treatments for the spine, ... institutional investors and,analysts at the Waldorf=Astoria Hotel in New ... to 7:30 p.m. ET. The reception will be ...
Cached Biology Technology:Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 3NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 4NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 5NuVasive to Host Investor Reception on September 11, 2007 2NuVasive to Host Investor Reception on September 11, 2007 3NuVasive to Host Investor Reception on September 11, 2007 4
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... United States and Europe has identified a single genetic mutation ... with and without diabetes. Albuminuria is a condition caused by ... is an indication of kidney disease. The research team, ... association studies to identify missense variant (I2984V) in the CUBN ...
... tiniest pollution particles which we take in with ... people more vulnerable to cardiovascular and respiratory problems. While ... showing exactly how it does so has been challenging. ... Environmental Health Perspectives , scientists showed that in ...
... an estimated 10,000 shipping containers fall off container ships at ... for months, most eventually sink to the seafloor. No one ... deep seafloor. From March 8 to March 10, 2011, ... National Marine Sanctuary (MBNMS) will use a robotic submarine to ...
Cached Biology News:Gene variant influences chronic kidney disease risk 2Pinpointing air pollution's effects on the heart 2Pinpointing air pollution's effects on the heart 3MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea 2MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea 3
Recombinant Mouse Noggin...
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Human VASA Biotinylated Affinity Purified PAb...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Biology Products: